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Proliferative and differentiative signals required for expression of helper and 
cytolytic T cell functions have been increasingly discerned through analysis of a 
family of multiple and functionally distinct monocyte- and lymphocyte-derived 
interleukins (1-8). Antigen-nonspecific cofactors also affect B cells and a complex 
series of differentiative and growth factors (9) have been identified as requisite 
signals in the antigen-initiated sequence that culminates in clonal expansion and 
antibody secretion. In contrast, the identity and role of such soluble factors in 
the expression of suppressor T cell (Ts) *  effector function are poorly understood. 
Interleukin 2 (IL-2) appears to be an obligate stimulus to the proliferation of 
helper/inducer (10,  11) and cytolytic (5-8) T  cells, as well as natural killer cells 
(11, 12); in addition, culture supernates that contain IL-2 also support Ts growth 
(11,  13-16).  However, studies involving the fungal metabolite cyclosporin A 
(CsA) suggest that Ts may have distinct or additional interleukin requirements 
in comparison with those of helper or cytolytic T  cells. Interference with IL-2 
production (17-20),  possibly  in concert with effects on IL-2  receptor display 
(20-22) and IL-1  generation (17,  19), appears to underlie CsA-mediated inter- 
ference with helper and cytolytic T  cell activation (17, 23-25).  In contrast, Ts 
function is  unaffected (20,  23,  26,  27),  implying that Ts  may use additional 
interleukins produced through CsA-resistant mechanisms. 
Thus,  to define specific and possibly  unique features of differentiative and 
proliferative signals required by Ts, we have developed a Ts costimulator assay. 
Initial studies using this assay have identified an antigen-nonspecific, genetically 
unrestricted soluble factor that is required, in addition to specific alloantigens 
on fixed stimulator cells, for the activation of alloantigen-primed Ts, designated 
MLR-Ts and characterized in previous studies (28). Ts costimulator activity has 
been identified in primary mixed leukocyte reaction (MLR) supernates and is 
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found in addition  in supernates of the  murine  thymoma EL4.  In both prepara- 
tions, however, Ts costimulator is distinct from IL-2. Ts activation to suppressor 
factor (MLR-TsF) production  is promoted by MLR-derived Ts costimulator in 
the absence of Ts proliferation, implying a  differentiative rather than prolifera- 
tive function, which suggests the provisional designation, Ts differentiative factor 
(TsDF). This initial characterization thus identifies one of a family of interleukins 
that are used, perhaps selectively, in the expression of Ts cell function. 
Materials and  Methods 
Mice.  BALB/cCrgl (BALB) mice were obtained from the Department of Cell Biology, 
Baylor College of Medicine. All other mice were purchased from The Jackson Laboratory, 
Bar Harbor, ME. All mice used were 6-10-wk old. 
Antibodies.  Monoclonal anti-Lyt-l.2 and anti-Lyt-2.2 hybridoma antibodies were pur- 
chased from New England Nuclear, Boston, MA. Monoclonal anti-Thy-l.2 antibody was 
prepared by ammonium sulfate fractionation of spent culture medium from the HO13.4.9 
hybridoma obtained originally from the Salk Institute, La Jolla, CA and provided by Dr. 
Ellen Vitetta, University of Texas Health Science Center, Dallas, TX. Monoclonal anti-I- 
jd, an ascites preparation of bybridoma WF18.2815,  was the generous gift of Dr. Carl 
Waltenbaugh, Northwestern University Medical School, Chicago, IL. 
Cyclosporin A.  Cyclosporin  A  (CsA),  obtained  as  a  gift  from  Sandoz  Ltd.,  Basel, 
Switzerland, was diluted to 5 mg/ml in 95% ethanol, stored at -70°C, and further diluted 
in supplemented Eagle's minimum essential medium (MEM) to  1.0/ag/ml in culture, an 
optimal concentration established by titration for nontoxic inhibition of MLR proliferation 
and IL-2 production. 
Production of MLR Supernates with Ts Costimulator Activity.  Bulk primary MLR cultures 
were established with 10 x  106/ml responder spleen cells and 5 x  106/ml irradiated (1,500 
rad) allogeneic or syngeneic stimulator spleen cells in supplemented MEM containing 5% 
heat-inactivated fetal calf serum (FCS).  MLR culture supernates were harvested after a 
48-h incubation at 37°C in  10%  CO2, 83%  Nz,  and 7%  02 by centrifugation at  1,000 
rpm followed by a second centrifugation of the supernate at 2,500 rpm. Supernates were 
stored at -70°C until use. 
Production oflL-2-containing  Supernates.  EL4 thymoma cells of a cloned subline devel- 
oped by Dr. J. Farrar, NIH and obtained from Dr. E. Vitetta were resuspended to  1 x 
106/ml in supplemented RPMI 1640 containing 1% FCS and 12.5 ng/ml phorbol myristic 
acetate (PMA) (Sigma Chemical Co., St. Louis, MO). Supernatants were harvested after a 
24-h  incubation,  and  the  IL-2-containing fraction  was  isolated  by  50-85%  saturated 
ammonium  sulfate  precipitation.  The  precipitate  was  dissolved  and  dialyzed  against 
phosphate-buffered saline (PBS) before final dialysis into Hepes-buffered Hanks' balanced 
salt solution (HBSS) and storage at -20°C. This EL4 supernate preparation was used as 
described below for the assessment of Ts costimulator activity. 
Additionally,  lectin-free concanavalin A (Con A) supernate was used as a standard  in 
IL-2 quantitation  by HT2  proliferation.  Mouse splenocytes were incubated  in  supple- 
mented RPMI  1640 containing 2% FCS and  10 #g/ml Con A (Sigma Chemical Co.) for 
2 h at 37°C in an atmosphere of 5% CO2. The cells were then centrifuged, washed, and 
resuspended  in  supplemented  RPMI  1640  containing  10%  FCS  and  incubated  for an 
additional 20 h. Supernates were harvested, filtered, and stored at -20°C until use. 
Ts Costimulator Assay.  Primed spleen cell populations containing MLR-Ts were pre- 
pared from mice immunized in  the  footpads 4  d  previously with  40  x  10  6  allogeneic 
splenocytes. Spleen cells from these animals or normal control animals were enriched for 
viable cells  with low ionic strength  medium (LISM) (29),  depleted of erythrocytes with 
Tris-NH4C1 buffer, and resuspended to 40 x  10  6 cells/ml in supplemented MEM with 2% 
FCS. Stimulator spleen cells of the MLR-Ts priming strain were irradiated (1,500 rad) or 
glutaraldehyde  fixed  by  incubation  of  15  x  l0 s  cells/ml  in  freshly  prepared  0.05% 
glutaraldehyde in HBSS for 15 min at 22°C. Fixed cells were washed twice in HBSS, and RICH, CARPINO,  AND  ARHELGER  1475 
both irradiated and fixed stimulator cells were resuspended to 40  X  106/ml in supple- 
mented MEM-2% FCS. Additional treatment of fixed cells with irradiation before or after 
fixation provided results identical to those achieved with fixation alone. Equal numbers 
of primed MLR-Ts-containing spleen cells and irradiated or fixed stimulator cells were 
combined, usually 20 ×  106 of each, in a total volume of 1.0 ml, and an equal volume of 
control medium or Ts costimulator-containing preparation was added in varying concen- 
trations.  MLR supernates were typically used at  1:2 and EL4 supernates at  1:100 final 
concentration.  These cultures were incubated for 48 h  at 37°C in  10%  CO2,  83%  N2, 
and 7% 02 and supernates were harvested by centrifugation at 2,500 rpm and stored at 
-70°C until assay for MLR-TsF activity, a period usually <2 wk. Negative control cultures 
contained  unprimed  cells  with  syngeneic  irradiated  stimulators  and  control  medium. 
Additional controls included control or Ts costimulator-containing supernates incubated 
48  h  as above in  the absence of suppressor and stimulator cells.  Primed  MLR-Ts are 
designated  in  the  text as the  MLR-Ts strain  followed by a  superscript indicating  the 
allogeneic priming strain (e.g., BALB~6). 
Proliferation in Ts costimulator assays was assessed by parallel culture of triplicate or 
quadruplicate  0.2-ml aliquots of the  MLR-Ts stimulator/MLR supernate mixtures that 
were cultured for MLR-TsF production. Cultures were incubated for 72 h under condi- 
tions used for MLR-TsF production, with 1 #Ci [3H]thymidine ([SH]TdR) added during 
the final 18 h. Cultures were harvested and processed for liquid scintillation counting as 
described below for MLR assays. 
Antibody and Complement Depletion of  MLR-Ts Cells.  Viable, primed MLR-Ts-containing 
spleen cells prepared by LISM and Tris-NH4CI buffer treatment were incubated at 20 x 
106/mi  with  monoclonal  anti-Thy-l.2  (1:30),  anti-Lyt-l.2  or  -2.2  (1:500),  or anti-I-J  d 
(I:100) antibodies at 4°C for 30 min and washed once. They were resuspended at 20 x 
106/ml  in  prescreened  young  rabbit  serum  (1:10)  as  a  complement source,  obtained 
through  the  generosity  of Dr.  R.  Baughn,  Veterans  Administration  Medical  Center, 
Houston, TX, and were incubated for 45 min at 37°C. After all cells were washed once, 
cells exposed to anti-Thy-l.2 and anti-Lyt antibodies were treated a  second time with 
antibodies and complement as before, and all treated groups were washed two to three 
additional cycles, depleted of dead cells by LISM treatment, and remaining viable cells 
resuspended as above for culture with irradiated or fixed stimulator cells for MLR-TsF 
production. 
Assay of MLR-TsF in MLR cultures.  MLR cultures in a  final volume of 0.2  ml were 
established  in  96-well  flat-bottom  microtiter  plates  with  106  each  of responder  and 
irradiated (1,500 rad) stimulator cells in supplemented MEM with  10% FCS and 0.1  ml 
of medium, control factor, or MLR-TsF in multiple concentrations. MLR responder cell 
strains were always H-2 syngeneic with  the  MLR-TsF-producing strain.  MLR cultures 
were incubated at 37°C in 10% CO2, 83% N~, and 7% 02 for 96 h, with 1 ~Ci [3H]TdR 
(sp act, 2 Ci/mmoi; New England Nuclear) added during the final  18 h. Cultures were 
harvested onto glass fiber filters using a MASH II apparatus (M. A. Bioproducts, Bethesda, 
MD) and processed for liquid scintillation counting. Data are expressed as Acpm +  SEM, 
representing  mean  cpm  of triplicate  cultures  with  stimulator  cells  allogeneic  to  the 
responder cell strain minus mean cpm of cultures with syngeneic stimulator cells. SEM of 
Acpm are calculated by the formula for the propagation of errors. Percent MLR suppres- 
sion is calculated as follows: [1  -  (Acpm of MLR with MLR-TsF)/(Acpm of MLR with 
medium or control factor)] ×  100. 
IL-2 Assay.  IL-2 activity was assayed by proliferation of the IL-2-dependent T  cell line 
HT2,  described by Dr. J.  Watson  (30)  and  obtained from Dr. J.  Kappler and  Dr.  P. 
Marrack, National Jewish Hospital and Research Center,  Denver, CO.  HT2 cells were 
washed and resuspended in supplemented RPMI 1640 and 5 x  10 s cells were cultured in 
the  presence  of serial  twofold dilutions  of IL-2-containing supernatants  as previously 
described (31).  [aH]TdR incorporation  was determined  during  the  last 4  h  of a  24  h 
culture period. Activity is presented as cpm vs. dilution of IL-2-containing supernatant. 
Adsorption oflL-2.  IL-2-containing supernates were depleted of IL-2 by incubation of 
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cells for 2.5  h  at 4°C.  Supernates  were collected by centrifugation  at  2,500  rpm and 
tested for residual IL-2 activity as above. 
Gel Filtration  Analysis.  MLR supernates  were  concentrated  by Minicon-B15  macro- 
solute concentration (Amicon Corp., Danvers, MA), dialyzed against 0.01  M PBS buffer, 
and fractionated on a  1.6  ×  100-cm calibrated Sephadex G 100 column (Pharmacia Fine 
Chemicals, Uppsala, Sweden) equilibrated in 0.01  M PBS.  3-ml fractions were collected, 
dialyzed against culture  medium, and assayed for IL-2 and  Ts costimulator activity as 
above. 
Results 
Activation  of MLR-TsF Production  in  a  Ts Costimulator Assay.  A  short-term Ts 
cell  costimulator  assay  was  developed  to  identify  stimuli  required  for  Ts  cell 
activation to TsF production. This assay was based on previous observations that 
glutaraldehyde-fixed stimulator cells fail to trigger the production of MLR-TsF 
normally obtained from primed MLR-Ts cultured with irradiated or mitomycin 
C-inactivated  stimulator  cells  (32).  It  was  possible  that  fixation  prevented  an 
activity in  the stimulator cell population  that was required  for primed  MLR-Ts 
proliferation or differentiation, and that was distinct from the display of alloan- 
tigen, which  is thought  to be largely unaffected (33).  Thus,  various cell culture 
supernates were tested for a soluble factor(s) that would reconstitute the missing 
stimulus  and  promote  MLR-TsF  production  when  added  to  primed  MLR-Ts 
and  fixed  stimulator  cells.  In  Fig.  1,  C57BL/6  (B6)-primed  BALB  MLR-Ts 
produced substantial MLR-TsF in response to irradiated but not glutaraldehyde- 
fixed B6 (B6c) spleen cells. However, supernate from a 48-h primary BALB anti- 
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FXGVRE  1.  Activation of MLR-TsF production  in a Ts costimulator assay. B6-primed BALB 
spleen  cells containing  MLR-Ts  were  cultured  with  irradiated  (B6) stimulators  (t)  with 
glutaraldehyde-fixed (B6G) stimulators alone (A) or with the additions of a 48-h primary BALB 
anti-B6 MLR supernate,  1:2 final concentration (A), or with BALB anti-B6 MLR supernate in 
the absence of stimulators (A). BALB anti-B6 MLR supernate was also incubated in the absence 
of MLR-Ts and stimulator  (+) as control.  Supernates  from these MLR-TsF production  or 
control cultures were harvested at 48 h and assayed for MLR-TsF content at concentrations 
shown in  BALB anti-SJL MLR. Data from a  representative  experiment  are expressed  as 
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B6  MLR  largely restored  MLR-TsF production by  MLR-Ts  co-cultured with 
fixed stimulators. In the absence of the fixed allogeneic stimulator population, 
primed MLR-Ts were unaffected by the supernate, suggesting that MLR super- 
nate activity was not independently stimulatory. Moreover, MLR supernate did 
not directly suppress the assay  MLR.  MLR-TsF was produced in dose-related 
response to MLR supernate in the Ts costimulator culture and demonstrated 
production kinetics  similar  to  those of standard  MLR-TsF  cultures  (data  not 
shown).  Thus, a  function required  for  the activation  of primed MLR-Ts and 
prevented directly or indirectly by stimulator cell fixation appeared to be sub- 
stantially reconstituted by a cofactor present in a primary MLR supernate. 
Specificity  Characterization  of  Ts  Costimulator  Activity  in  Primary  MLR  Super- 
hates.  To characterize antigen specificity of Ts costimulator activity, supernates 
were harvested from primary MLR composed of various responder and stimu- 
lator strains or of stimulator cells alone and examined for costimulator activity 
in  relation  to  MLR-Ts  stimulator  ailoantigens  (Table  I).  BALB  a6  MLR-Ts 
cultured with fixed B6 stimulator cells produced substantial MLR-TsF with the 
addition of BALB anti-B6 MLR supernate but not with supernates of unstimu- 
lated  BALB  splenocytes  or  of B6  stimulators  cultured  alone.  Primary  MLR 
supernates prepared in response to H-2 and minor alloantigens identical to or 
distinct  from  those  used  to  prime  and  restimulate  MLR-Ts  each  expressed 
effective  Ts  costimulator  activity  with  B6-primed  BALB  MLR-Ts.  Similarly, 
MLR supernates prepared with responder cells identical to or dissimilar from 
the MLR-Ts strain with regard to H-2 or non-H-2 (including Igh) genotype were 
also equally effective. Thus, neither strain restriction nor alloantigen specificity 
limit the Ts costimulator property. MLR-Ts-stimulator strain combinations other 
than BALB anti-B6 provided similar results (data not shown). Again, none of the 
primary MLR supernates were directly suppressive of assay MLR.  In addition, 
MLR-Ts precursors from unprimed rather than primed BALB spleens were not 
induced to  significant  TsF  production  within  the  48-h  culture period  in  the 
presence of either syngeneic or allogeneic fixed stimulators and Ts costimulator- 
containing MLR supernate. Together these findings differ from characteristics 
reported for Ts inducer or first-order Ts factors, including antigen specificity, 
VH restriction, and the induction of Ts from unprimed precursors (34). Instead, 
Ts costimulator characteristics suggest a closer alignment with the lymphocyte- 
and monocyte-derived family of interleukins. 
MLR-Ts  Population  Requirements for Expression  of Ts Costimulator  Activity.  Ts 
costimulator activity results in the release of MLR-TsF, a product of Thy-1 +, Ly- 
2 +,  I-J+C  + lymphocytes (35,  36).  To determine  if Ts  costimulator expression 
directly or indirectly requires an  intermediary  Ly-l+2  -  cell, primed MLR-Ts- 
containing spleen cells were depleted of cell subsets by antibody and complement 
lysis and remaining viable  cells were  cultured  for  MLR-TsF production with 
fixed stimulators and primary MLR supernates (Table II). Absence of Thy-1 +, 
Ly-2  ÷, or I-J  + cells from the MLR-Ts population prevented MLR-TsF produc- 
tion. In contrast, Ts costimulator-induced MLR-TsF production was unaffected 
by the depletion of cells bearing abundant Ly-1, suggesting that the expression 
of Ts costimulator activity does not require this population of Ly-1 + cells or their 
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TABLE  I 
Specificity Characterization of Ts Costimulator Activity in MLR Supernates 
MLR-TsF production culture* 
MLR-Ts  Stimulator 
MLR assay* 
MLR supernate  Percent 
Acpm  suppres- 
Responder  Stimulator  sion 
BALB  BALB 
BALB  B6  B6 
BALB  B6  B6G 
BALB  BALBG 
BALB  B6G 
--  --  30210  0 
--  --  29142  4 
--  --  11087  63 
--  --  28841  5 
BALB  BALB  27793  8 
--  B6  27189  I0 
BALB  B6  15619  48 
BALB  SJL  17242  43 
BALB  CBA  6927  77 
BI0.D2  B6  17465  42 
DBA/1  B6  10742  64 
SJL  B6  8604  71 
CBA  B6  16145  47 
BALB  B6  30814  -2 
--  --  24772  18 
BALB  B6  27189  10 
BALB  BALB  29303  3 
--  B6  31720  -5 
BALB  B6  28218  7 
BALB  SJL  30735  -2 
BALB  CBA  30540  - 1 
B10.D2  B6  35268  -17 
DBA/1  B6  30423  -1 
SJL  B6  26432  12 
CBA  B6  34692  14 
* MLR-TsF  production cultures were  prepared with B6-primed  or unprimed BALB spleen cells, 
irradiated (BALB, B6) or glutaraldehyde-fixed  (BALBG, B6G) stimulator splenocytes and control 
medium or supernate of a 48-h primary MLR at final concentration of 1:2. These were cultured 
for 48 h before harvest of supernates for MLR-TsF assay. To control for direct suppressive effects 
of primary MLR supernates,  the MLR supernates were also incubated in the absence of MLR-Ts 
and stimulator populations and assayed as for MLR-Ts containing  MLR-TsF production cultures. 
* MLR-TsF-containing  supernates were assayed in multiple concentrations in MLR of BALB re- 
sponder and irradiated BALB or SJL stimulator spleen cells. Data represent MLR-TsF at 20% final 
volume and are from a representative experiment. 
Distinction  Between  Ts Costimulator Activity  and IL-2.  Because supernates that 
contain IL-2 have also been reported to support Ts function (37, 38), we wished 
to determine if costimulator activity was directly associated with or distinct from 
the IL-2 that was present in the MLR supernates. In an initial approach,  MLR 
supernates were depleted of IL-2 by adsorption with the cloned IL-2-dependent 
HT2  T  cell line and then assayed for residual IL-2 activity by HT2  proliferation 
and for Ts costimulator activity by MLR-TsF production in the Ts costimulator RICH, CARPINO,  AND  ARHELGER  1479 
TABLE II 
MLR-Ts Population Requirements  for Expression of Ts Costimulator Activity 
MLR-TsF production  culture* 
MLR-Ts  Treatment  Stimulator 
MLR assay* 
MLR  Percent 
super-  Acpm  sup.pres- 
nate  slon 
BALB 
BALB  B~ 
BALB  B~ 
BALB  B6 
--  --  -  26,600  0 
--  BALB  -  21,546  19 
B6  -  8,512  68 
B6c  -  22,344  16 
--  B6G  +  15,960  40 
C only  B6G  +  14,630  45 
a-Thy-1 + C  B6G  +  23,541  11 
a-Ly-I + C  B6c  +  15,162  43 
a-Ly-2 + C  B6G  +  21,546  19 
ot-J d +  C  B6o  +  20,615  12 
--  --  +  24,472  8 
*  B6-primed BALB spleen cells were untreated or treated with antibody  and 
complement or complement alone. Viable cells were isolated, combined with 
irradiated  (B6) or fixed (B6G) stimulator splenocytes and BALB anti-B6 48-h 
primary MLR supernate at 1:2 final dilution, cultured for 48 h, and supernates 
harvested. A control group consisted of MLR supernates incubated 48 h in the 
absence of MLR-Ts and stimulators. 
* MLR-TsF-containing supernates or control  MLR supernates were assayed in 
multiple concentrations in MLR of BALB responder and BALB or SJL stimu- 
lators.  Data represent MLR-TsF at 20% final volume and are from one of 
three similar experiments. 
assay  (Fig.  2).  Unadsorbed  48-h  primary  MLR  supernates  typically  expressed 
modest IL-2 activity (Fig.  2,  inset) and  did not  contain  material suppressive of 
IL-2  utilization  (legend,  Fig.  2).  HT2  adsorption  removed  IL-2  activity,  but 
failed to diminish  Ts costimulator function;  HT2-adsorbed  MLR supernate  or 
control  medium were  not  directly suppressive.  Thus  Ts costimulator and  IL-2 
activities appear to be distinct. 
An  alternative  approach  was developed  from the  observation that  CsA pro- 
hibits IL-2 production (17-20),  yet permits Ts function (20, 23,  26, 27).  Super- 
nates were collected from BALB anti-B6 MLR that were cultured in the absence 
or presence of CsA, dialyzed extensively, and assayed for IL-2 and Ts costimu- 
lator activity (Fig.  3).  Supernates  prepared with CsA lacked IL-2 activity while 
the MLR-Ts-activating property was unaffected. MLR supernates prepared with 
CsA or culture medium incubated with CsA (data not shown) were not directly 
suppressive.  These  data  again  strongly suggest  that  Ts costimulator  activity is 
distinct from IL-2; moreover, Ts costimulator production appears to be resistant 
to CsA and may contribute to the protected development of Ts in its presence. 
The relationship of IL-2 and Ts costimulator activities was also characterized 
by gel  chromatography (Fig.  4).  Concentrated  BALB anti-B6  MLR  supernate 
was  applied  to  a  G100  column  and  collected  fractions  were  dialyzed  against 
culture  medium  and  tested  for  IL-2 activity by HT2  proliferation  at  multiple 
dilutions  and  for  MLR-Ts  costimulator  activity at  a  I:2  final  dilution.  Major 
peaks of IL-2 and  Ts costimulator activities were largely distinct.  IL-2 activity 1480  SUPPRESSOR  T  CELL  COFACTORS  DISTINCT  FROM  INTERLEUKIN  2 
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FIGURE 2.  Ts costimulator activity in HT2-adsorbed MLR supernates. Undiluted primary 
BALB anti-B6 MLR supernates were untreated (A, x) or incubated with 20 x  104 HT2 cells] 
ml for 2.5 h at 4°C to deplete IL-2 (A, *) before addition to BALB  ~  MLR-Ts and fixed (B6G) 
stimulators. HT2-adsorbed culture medium (MDM-5) (O) was also used as a control. Resultant 
MLR-TsF or  MLR supernates cultured alone were assayed as in Fig.  1.  Inset depicts IL-2 
activity,  measured  by  HT2  proliferation,  of a  Con  A-induced,  lectin-free  IL-2  standard 
supernate (O),  unadsorbed MLR supernate (&), and HT2-adsorbed MLR supernate (x). The 
addition of unadsorbed MLR supernate,  1:3 final volume, to an assay of the IL-2 standard 
supernate had no effect on standard 1L-2 quantitation (data not shown). 
eluted in the 28-32,000  tool wt region while two peaks of 19,000-23,000 and 
40,000-45,000 mol wt contained costimulator activity; a shoulder ofcostimulator 
activity at 28,000 tool wt was approximately coincident with the IL-2 peak. None 
of the MLR supernate  fractions were suppressive when added directly to assay 
M LR, and G 100-chromatographed control M LR culture medium containing 5% 
FCS  neither  contained  Ts  costimulator  activity  nor  directly  suppressed  assay 
MLR (data not shown). Thus, Ts costimulating activity exists in two major peaks 
of approximately 21,000 and 43,000 mol wt that are largely independent of IL- 
2-containing fractions. 
Expression  of Ts  Costimulator  Activity  in  EL4  Supernates.  The  supernates  of 
PMA-induced  EL4  thymoma  cells  are  a  potent  source  of IL-2  activity,  and 
distinct B cell reactive lymphokines have also been identified in these supernates 
(9,  39).  Thus  it  was of interest  to determine  if standard  EL4  supernates  also 
contained  Ts  costimulator  activity and  if this  activity  could  be  differentiated 
from IL-2. MLR-Ts costimulator assays were established with MLR supernates 
or with dilutions of a standard  EL4 supernate.  After 48 h, the MLR-Ts culture 
supernates were harvsted, adsorbed with HT2 cells to remove residual IL-2, and 
assayed for MLR-TsF activity (Fig.  5); as demonstrated in previous studies (31) 
and confirmed here, HT2 adsorption of conventional MLR-TsF does not inter- RICH,  CARPINO,  AND  ARHELGER  1481 
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FIGURE 3.  Ts costimulator activity in MLR supernates prepared with CsA. BALB anti-B6 
MLR supernates were prepared in the absence (A, x) or presence (A,  *) of 1 ~g]ml CsA, 
dialyzed, added to BALB  MLR-Ts and fixed stimulators, and assayed for activation of MLR- 
TsF production as in previous figures. Inset shows IL 2 activity, measured by HT2 prolifera- 
tion, of an IL-2 standard as in Fig. 2 (0), untreated MLR supernate (A), and CsA-treated 
supernate (x). 
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FIGURE 4.  Ts  costimulator  and IL-2  activities  in  G 100  fractions  of  primary  MLR  supernates. 
Primary  BALB anti-B6  M LR sul)ernates  were  G 100  chromatographed  and  aliquots  of  dialyzed 
fractions  were added to BALW'° MLR-Ts and irradiated  (B6)  or fixed  (B6c)  stimulators  at  a 
1:2 final concentration. Resultant MLR-TsF (20% final concentration) was assayed in BALB 
anti-SJL MLR; data are provided as the percent MLR suppression (0). Fraction aliquots were 
also added to HT2-proliferative assays at multiple dilutions; maximal proliferation, in all cases 
observed at 1:2 final concentration, is provided as cpm of [SH]TdR incorporated by HT2 (O). 
fere with TsF function.  MLR-Ts  costimulator cultures that received EL4 super- 
hate,  in  addition  to  those  receiving MLR  supernate,  were  activated in  a  dose- 
related  fashion  to  MLR-TsF  production,  suggesting  that  EL4  supernates  also 
contain  an  activity  effective  in  MLR-Ts  activation.  In  this  and  the  following 1482  SUPPRESSOR  T  CELL  COFACTORS  DISTINCT FROM INTERLEUKIN  2 
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FIGURE 5.  Ts costimulator activity in EL4 supernates. EL4 supernate, prepared as described 
in Materials and Methods, at 1:I 00 ([-1) or 1:200 (i2--.--E]) final concentration or BALB  anti- 
B6 MLR supernate at 1:2 (A) final concentration were added to BALB  m MLR-Ts and fixed 
(B6G) stimulators. Except for the positive control group designated with an asterisk (*BALBm), 
MLR-TsF from all cultures or EL4 and MLR supernates cultured alone (data not shown) were 
adsorbed with HT2 cells to remove residual IL-2 before assay in BALB anti-SJL MLR. In this 
and Fig. 6, higher EL4 concentrations did not have greater activity. 
studies, HT2-adsorbed EL4 supernates were not suppressive when added directly 
to assay MLR (data not shown). 
To determine if the Ts costimulator activity in EL4 supernates was the result 
of IL-2 or of a  distinct material, EL4 supernates were adsorbed with HT2 cells 
to remove IL-2 before their addition to the MLR-Ts costimulator assay (Fig. 6). 
As with HT2-adsorbed MLR supernates, IL-2-depleted EL4 preparations clearly 
expressed substantial  Ts costimulator activity. Although  these  experiments do 
not address the role that IL-2 may also play, it appears evident that a  material 
expressing MLR-Ts costimulator activity and  distinct  from IL-2 exists in  EL4 
supernates. 
Ts  Costimulator  Activity  in  the  Absence of MLR-Ts  Proliferation.  In  an  initial 
approach we wished to examine the  nature of the Ts costimulator function(s), 
i.e., proliferative or differentiative, that supports activation of MLR-Ts.  If the 
primary function is proliferation of the MLR-TsF-producing cell pool, it would 
be anticipated that the expression of Ts costimulator activity would be inhibited 
by prevention of response to proliferative signals.  Therefore MLR supernates 
were added to Ts costimulator assays in which the BALB  B6 MLR-Ts population 
was either irradiated (1,500 rad) or untreated (Fig.  7).  Ts costimulator activity 
was assayed by MLR-TsF production, and MLR-Ts proliferation was assessed by 
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FIGURE 6.  Ts costimulator activity in HT2-adsorbed  EL4 supernates.  EL4 or MLR super- 
nates were depleted of IL-2 activity by HT2  adsorption as in Fig.  2  before  the addition, at 
I:100  (F'I  r-l), 1:150  ([3----[21),  or  1:200  ([21-.--[])  final concentration,  of adsorbed  EL4 
supernate or  1:2 (A--A)  final concentration  adsorbed  MLR supernate  to BALB m  MLR-Ts 
and fixed B6c stimulators.  MLR-TsF  from these cultures  was assayed  in BALB anti-B10.S 
MLR.  Inset shows IL-2 activity, measured by HT2 proliferation, of an IL-2 standard lectin- 
free Con A supernate (O), untreated EL4 supernate (1:50) (k  A), and HT2-adsorbed EL4 
supernate (1:50) (×). 
production  by  irradiated  MLR-Ts  was  decreased  but  still  clearly  present  in 
positive control cultures with irradiated stimulator ceils. Significantly, the capac- 
ity of Ts costimulator to induce TsF production was unaltered by irradiation of 
the MLR-Ts population. These data imply a costimulator function that does not 
act  via proliferative  stimulus,  but rather  appears  to  reflect  the  induction  of a 
differentiative  process  required  for  TsF secretion.  For simplicity of reference, 
the MLR-Ts costimulating activity represented  in primary  MLR supernates has 
been provisionally termed Ts differentiation factor (TsDF). 
Discussion 
In  this  report  we  describe  a  Ts  costimulating  factor  that  synergizes  with 
alioantigens on fixed stimulator cells to induce MLR-TsF production by alloan- 
tigen-primed MLR-Ts.  Based on several functional criteria the Ts costimulating 
property  appears  to  be distinct  from  the  class of soluble  factors  with antigen- 
specific, Ts-inducing qualities, and instead to be most closely associated with the 
regulatory  interleukins.  Functional and molecular  weight characteristics  differ- 
entiate Ts costimulator in both primary MLR and induced EL4 supernates from 
the  T  cell  lymphokine  IL-2,  and  indirect  evidence  discussed  below  suggests 
distinction  from  IL-I  and  gamma  interferon  (IFN-7)  as  well.  Thus  the  Ts 
costimulator factor(s) described  here, and specifically the differentiative activity 1484  SUPPRESSOR  T  CELL  COFACTORS  DISTINCT  FROM  INTERLEUKIN  2 
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FIGURE 7.  Expression of Ts constimulator activity in the absence of MLR-Ts proliferation. 
BALB anti-B6 MLR supernates were added to untreated (A--A) or irradiated (A--A) BALB  ~ 
MLR-Ts and fixed (B6G) stimulators. In addition, untreated (0)  or irradiated (O)  BALB  ~ 
MLR-Ts were also cultured with irradiated B6 stimulators. Resultant MLR-TsF was assayed 
in BALB anti-SJL MLR; proliferation was assessed by [SH]TdR incorporation into aliquots of 
MLR-Ts cultures as described in Materials and Methods. 
termed TsDF, may constitute distinctive members of the family of interleukins 
required in the antigen-driven activation of Ts to effector function. 
In several murine and human suppressor T  cell systems, primed and restim- 
ulated  T  cells  termed,  alternatively,  suppressor  inducers  (Tsi)  or  first-order 
suppressor cells (Tsl),  or their soluble products,  induce a  subset of T  cells to 
effector suppressor activity from unprimed precursors (40-48).  In so doing they 
impart  antigen  specificity  to  the  induced  Ts,  either  for  the  antigen  used  to 
stimulate the Tsi (40, 41) or for determinants serologically described as idiotypic 
and assumed to exist on the Tsi antigen-binding receptor (42-44).  Additional 
specificity of Ts inducer-Ts precursor interaction may be imposed by Vu restric- 
tions (40). Soluble products of murine Tsi express antigen-binding sites, idiotypic 
or  V.  determinants,  and  in  most  cases  I-J  determinants  (34);  from  affinity 
column analyses  these determinants exist on a  molecule(s) both required and 
sufficient  to  initiate  Ts  function  (41,  45-47).  These  inducer  molecules  may 
provide the antigenic and perhaps the major histocompatibility complex-encoded 
elements required to initiate Ts precursor activation; clearly,  they are distinct 
from the antigen-nonspecific, nonrestricted,  hormone-like factors  classified as 
interleukins. Similarly, the Ts costimulator preparations described here are also 
distinct from Ts-inducing factors in several respects,  including lack of antigen 
specificity and genetic restriction, production early in a primary response rather 
than after priming and restimulation, and failure to activate naive Ts.  BALB/ RICH,  CARPINO,  AND  ARHELGER  1485 
c B~  MLR-Ts  activation  was  achieved  with  Ts  costimulator  preparations  that 
violate both H-2  (CBA,  SJL,  DBA/1  costimulator sources) and IgH (B10.D2, 
DBA/1, SJL sources) restrictions. In addition, although the alloantigenic stimuli 
of MLR-Ts and of Ts costimulator production are each potentially complex, no 
general  strain-associated  alloantigen  specificity  of Ts  costimulator  effect  was 
apparent.  Moreover,  Ts  costimulator promotes ~ctivation  of primed but  not 
naive  Ts  within  the  limited  time  frame  analyzed,  while  Ts-inducing  factors 
generally fail to affect primed Ts (44,  49,  50).  These qualities thus appear to 
characterize Ts costimulator activity as a function of an interleukin-like material 
and distinguish it from the antigen-specific Ts inducers. 
The  interpretation  that  Ts  costimulator  activity  is  mediated  by  molecules 
distinct from IL-2  is supported by each of the approaches to determining the 
relationship of these two activities. Thus Ts costimulator function is retained in 
HT2-adsorbed, IL-2-deficient supernates, is generated in cultures in which IL-2 
production  is  blocked  by  CsA,  and  demonstrates  distinct  molecular  weight 
characteristics.  Moreover,  proliferation  is  not  required  for  Ts  costimulator 
expression.  The presence of Ts  costimulator activity as a  component of EL4 
supernate  distinct  from  IL-2  is additionally  interesting  in  light  of the  recent 
identification of an  18,000  mol wt fraction containing a  B  cell growth factor 
(BCGF) (39) and a  late-acting B  cell differentiative cofactor termed EL4-TRF 
(9) in PMA-induced supernates of the same EL4 subline. The relationship of Ts 
costimulator to these B  cell-related cofactors, or to other characterized T  cell 
and macrophage-derived factors has not yet been directly examined, although 
the reported susceptibility of IL-I  (17,  19) and IFN-3, (51) production to CsA 
suggest that these factors are not mediators of the Ts costimulation described in 
this report. In addition, the present studies do not yet allow the conclusion that 
the material in EL4 supernates and that characterized in primary MLR super- 
nates  are  biochemically  or  functionally  identical.  Each  demonstrates  Ts  co- 
stimulator activity but may achieve that activity by distinct mechanisms. More- 
over, it is not clear if the  MLR supernate-derived 43,000  and 21,000  mol wt 
fractions expressing costimulator activity represent distinct species or complexed 
forms of a single molecule. Finally, although this Ts costimulator activity is not 
apparently mediated by IL-2, additional roles of IL-2 or other lymphokines in 
support of the process of MLR-Ts activation to TsF production have not been 
directly approached in these studies and are clearly possible. Complex IL-2-rich 
culture supernates have been used in the promotion of Ts activity (37,  38) and 
maintenance of long-term Ts lines (11,  13-16); however, Ts utilization of I L-2 
per se as a proliferative trigger has not yet been formally demonstrated. 
The production of Ts  costimulator in  the presence  of CsA  has  interesting 
implications concerning interleukin stimuli that contribute to Ts function. Al- 
though  CsA  effects  appear  to  be  complex and  somewhat  controversial,  it  is 
generally appreciated that CsA prohibits IL-2 production by alloantigen-activated 
T  cells (17-20); as previously stated, it appears that the generation of IFN-~, (51) 
and IL-1 (17,  19) are also interrupted. In contrast, Ts costimulator is produced 
in primary MLR cultures in the presence of CsA, and in the absence of IL-2. 
Activation of Ts costimulator-producing cells thus appears to be CsA resistant 
and to occur in the absence of both IL-1 and IL-2 differentiative and proliferative 1486  SUPPRESSOR  T  CELL  COFACTORS  DISTINCT  FROM  INTERLEUKIN  2 
support.  Hess  et al.  (52)  and  more recently  Mohagheghpour et al.  (53)  have 
demonstrated T4 ÷ or Leu-3+8 + cells, respectively, in CsA-suppressed MLR of 
human cells, which appear to be required for expression of T8 ÷ suppressor cell 
function.  Such cells thus may be  the CsA-resistant producers of Ts-associated 
factors such as the Ts costimulator described here. 
An alloantigen-primed MLR-Ts population and fixed stimulator cells bearing 
priming alloantigens are required in the Ts costimulator assay.  It is clear that 
alloantigen  recognition  by  primed  cells  is  necessary  for  interaction  with  Ts 
costimulator and is achieved with glutaraldehyde-fixed stimulators. Thus antigen 
binding may trigger the expression of TsDF or other Ts costimulator-specific 
receptors on primed MLR-Ts, allowing subsequent cofactor interaction. In the 
absence of Ts costimulator, activation to MLR-TsF production fails regardless 
of stimulator cell concentration,  indicating that fixation has impaired an addi- 
tional and requisite stimulator cell function distinct from surface antigen display. 
MLR-Ts typically interact with stimulator cells of novel I-C + or I-J+C ÷ phenotypes 
(54). Whether Ts costimulator directly represents an activity of such a stimulator 
cell  or  rather  the  product  of  a  secondary  cell  that  requires  stimulator  cell 
interaction  is presently unclear.  Furthermore,  the immediate target of Ts  co- 
stimulator in the primed MLR-Ts-containing population has not been directly 
established  in  these studies.  It  is evident  that  T  cells bearing abundant  Ly-I 
alloantigen and routinely removed by anti-Ly-1 antibody-mediated lysis are not 
target cell candidates. In addition, under usual conditions of MLR-Ts reactiva- 
tion,  MLR-TsF production is insensitive to rigorous macrophage depletion of 
both MLR-Ts and stimulator populations (32), suggesting indirectly that these 
cells  are  also  unlikely  Ts  costimulator  targets.  Similarly,  based  on  depletion 
protocols, B cells play no requisite role in MLR-Ts activation (S.  Rich and C. 
Arhelger,  unpublished observations).  Thus the most likely although unproven 
target  exists  in  the  Ly-2  ÷,  I-J+C +  MLR-Ts  population.  The  observation  that 
primed but not unprimed cells are responsive t °  Ts costimulator in concert with 
alloantigen may reflect the expression of a late-appearing cofactor requirement, 
presumably  differentiative,  for  the  final  expression  of Ts  effector  function. 
Alternatively, this cofactor requirement may be more generally expressed after 
antigen recognition and simply require extended culture of unprimed cells for 
measurable effect. 
Production of MLR-TsF is the endpoint of Ts cofactor activity defined by this 
costimulator  assay.  An  ordered  and  complex  series  of  interleukin-mediated 
differentiative and proliferative events have been described after initial antigen- 
receptor interaction in the functional development of IL-2-producing helper T 
cells, cytotoxic T  lymphocytes, and antibody-producing B cells. It is likely that 
Ts will demonstrate a similar scheme of activation. In this initial characterization, 
unfractionated MLR supernates minimally contain a  Ts cofactor that fulfills a 
differentiative  requirement  of antigen-activated  MLR-Ts.  It  will  now  be  of 
substantial  interest  to examine the contributions of purified TsDF,  IL-2,  and 
other differentiative and  proliferative cofactors in  control of Ts activation  to 
effector function. RICH, CARPINO, AND ARHELGER  1487 
Summary 
This report describes a Ts costimulator assay and its use to analyze cofactors 
required for the expression of suppressor T  cell function. Activation of primed 
MLR-Ts (alloantigen-activated suppressor T cells suppressive of mixed leukocyte 
reaction)  to  suppressor  T  cell  factor  (TsF)  production  typically fails  in  the 
presence of glutaraldehyde-fixed rather  than  irradiated  allogeneic stimulator 
cells.  However,  MLR-TsF  production  was  restored  by  the  addition  of 48-h 
primary  MLR  supernates;  MLR-derived  Ts  costimulator  neither  activated 
primed  MLR-Ts  in  the  absence  of fixed allogeneic  stimulators  nor  directly 
suppressed assay  MLR.  Lack of antigen  specificity or  genetic restriction and 
failure to activate unprimed MLR-Ts precursors suggested that Ts costimulator 
activity differed from previously described Ts inducer functions and was more 
closely aligned  with  the  lymphocyte- or  monocyte-derived interleukins  (IL). 
Three  findings  distinguished  Ts  costimulator  from  IL-2.  Depletion  of IL-2 
activity from MLR supernates by HT2 adsorption failed to affect Ts costimulator 
function. In addition, MLR supernates prepared in the presence of cyclosporin 
A  contained no IL-2 but expressed Ts costimulator activity. Finally, gel chro- 
matography demonstrated Ts costimulator in peaks of 21,000 and 43,000  moi 
wt that were largely distinct from the IL-2-containing fractions. Ts costimulator 
activity  was  also  identified in  phorbol  myristate acetate  (PMA)-induced EL4 
supernates and was retained in  those supernates after IL-2 depletion by HT2 
adsorption. In preliminary functional characterization, MLR supernate-derived 
Ts costimulator triggered MLR-TsF production from irradiated MLR-Ts in the 
absence of proliferation. Thus a differentiative rather than proliferative stimulus 
required  for  primed  MLR-Ts  function  appears  to  be  provided  by  this  Ts 
costimulator and has been provisionally termed Ts differentiative factor (TsDF). 
This initial characterization may thus identify one of a possibly distinctive family 
of interleukins required in the alioantigen-driven activation of suppressor T  cells 
to effector function. 
We thank Sue Floyd for excellent secretarial  assistance and Henry Juguilon for expert 
animal husbandry. 
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